Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

The gendered effects of foreign investment and prolonged state ownership on mortality in Hungary: an indirect demographic, retrospective cohort study.

Scheiring G, Stefler D, Irdam D, Fazekas M, Azarova A, Kolesnikova I, Köllő J, Popov V, Szelenyi I, Marmot M, Murphy M, McKee M, Bobak M, King L.

Lancet Glob Health. 2018 Jan;6(1):e95-e102. doi: 10.1016/S2214-109X(17)30391-1. Epub 2017 Nov 27.

2.

The effect of rapid privatisation on mortality in mono-industrial towns in post-Soviet Russia: a retrospective cohort study.

Azarova A, Irdam D, Gugushvili A, Fazekas M, Scheiring G, Horvat P, Stefler D, Kolesnikova I, Popov V, Szelenyi I, Stuckler D, Marmot M, Murphy M, McKee M, Bobak M, King L.

Lancet Public Health. 2017 Apr 11;2(5):e231-e238. doi: 10.1016/S2468-2667(17)30072-5. eCollection 2017 May.

3.

Mortality in Transition: Study Protocol of the PrivMort Project, a multilevel convenience cohort study.

Irdam D, King L, Gugushvili A, Azarova A, Fazekas M, Scheiring G, Stefler D, Doniec K, Horvat P, Kolesnikova I, Popov V, Szelenyi I, Marmot M, Murphy M, McKee M, Bobak M.

BMC Public Health. 2016 Jul 30;16:672. doi: 10.1186/s12889-016-3249-9.

4.
5.

Flupirtine, a re-discovered drug, revisited.

Szelenyi I.

Inflamm Res. 2013 Mar;62(3):251-8. doi: 10.1007/s00011-013-0592-5. Epub 2013 Jan 16. Review.

PMID:
23322112
6.

Soft drugs for future treatment of chronic obstructive pulmonary disease (COPD).

Szelenyi I.

Pharmazie. 2012 May;67(5):371-3. Review.

PMID:
22764565
7.

Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases.

Szelenyi I.

Inflamm Res. 2012 Jan;61(1):1-9. doi: 10.1007/s00011-011-0393-7. Epub 2011 Nov 5. Review.

PMID:
22057873
8.

Current animal models of bronchial asthma.

Kurucz I, Szelenyi I.

Curr Pharm Des. 2006;12(25):3175-94. Review.

PMID:
17020527
9.

Are there any realistic chances to develop new drugs for asthma?

Amon A, Pahl A, Szelenyi I.

Drug News Perspect. 2006 May;19(4):189-200. Review.

PMID:
16823494
10.

Is asthma research in dead end?

Amon A, Pahl A, Szelenyi I.

Exp Toxicol Pathol. 2006 Jun;57 Suppl 2:45-7. Epub 2006 Apr 11. Review.

PMID:
16581236
11.

Can corticosteroids be beaten in future asthma therapy?

Amon A, Pahl A, Szelenyi I.

Pharmazie. 2006 Feb;61(2):122-4. Review.

PMID:
16526559
12.

Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.

Baeumer W, Szelenyi I, Kietzmann M.

Expert Rev Clin Immunol. 2005 May;1(1):27-36. doi: 10.1586/1744666X.1.1.27.

PMID:
20477652
13.

The real gordian knot: racemic mixtures versus pure enantiomers.

Szelenyi I, Geisslinger G, Polymeropoulos E, Paul W, Herbst M, Brune K.

Drug News Perspect. 1998 Apr;11(3):139-60.

PMID:
15616615
14.

Bioavailability of diclofenac potassium at low doses.

Hinz B, Chevts J, Renner B, Wuttke H, Rau T, Schmidt A, Szelenyi I, Brune K, Werner U.

Br J Clin Pharmacol. 2005 Jan;59(1):80-4.

15.

Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate.

Szelenyi I, Hermann R, Petzold U, Pahl A, Hochhaus G.

Pharmazie. 2004 May;59(5):409-11.

PMID:
15212311
16.

New evidence for the selective, long-lasting central effects of the brain-targeted estradiol, Estredox.

Tapfer MK, Sebestyen L, Kurucz I, Horvath K, Szelenyi I, Bodor N.

Pharmacol Biochem Behav. 2004 Mar;77(3):423-9.

PMID:
15006452
17.

Efforts to standardize animal sensitization in asthma research. Scientific cooperation - quo vadis?

Szelenyi I.

Inflamm Res. 2003 Oct;52(10):397-8. No abstract available.

PMID:
14520513
18.

Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways.

Szelenyi I, Hochhaus G, Heer S, Kusters S, Marx D, Poppe H, Engel J.

Drugs Today (Barc). 2000 May;36(5):313-20.

PMID:
12861354
19.

Therapy of bronchial asthma with adenosine receptor agonists or antagonists.

Marx D, Ezeamuzie CI, Nieber K, Szelenyi I.

Drug News Perspect. 2001 Mar;14(2):89-100.

PMID:
12819800
20.

Unconventional therapies in asthma.

Szelenyi I, Brune K.

Drugs Today (Barc). 2001 Oct;37(10):651-664.

PMID:
12738963
21.

Herbal remedies for asthma treatment: between myth and reality.

Szelenyi I, Brune K.

Drugs Today (Barc). 2002 Apr;38(4):265-303. Review.

PMID:
12532195
22.

Asthma therapy in the new millennium.

Pahl A, Szelenyi I.

Inflamm Res. 2002 Jun;51(6):273-82. Review.

PMID:
12088267
23.

Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids.

Marx D, Tassabehji M, Heer S, Hüttenbrink KB, Szelenyi I.

Pulm Pharmacol Ther. 2002;15(1):7-15. Review.

PMID:
11969359
24.

Anti-inflammatory effects of a cyclosporine receptor-binding compound, D-43787.

Pahl A, Zhang M, Török K, Kuss H, Friedrich U, Magyar Z, Szekely J, Horvath K, Brune K, Szelenyi I.

J Pharmacol Exp Ther. 2002 May;301(2):738-46.

PMID:
11961080
25.

Regulation of IL-13 synthesis in human lymphocytes: implications for asthma therapy.

Pahl A, Zhang M, Kuss H, Szelenyi I, Brune K.

Br J Pharmacol. 2002 Apr;135(8):1915-26.

26.

Effects of antihistamines on leukotriene and cytokine release from dispersed nasal polyp cells.

Küsters S, Schuligoi R, Hüttenbrink KB, Rudert J, Wachs A, Szelenyi I, Peskar BA.

Arzneimittelforschung. 2002;52(2):97-102.

PMID:
11878205
27.

Drug therapy in asthma bronchiale in the new millennium.

Szelenyi I, Pahl A.

Pharmazie. 2002 Feb;57(2):83-6. Review.

PMID:
11878194
28.

Animal models of chronic obstructive pulmonary disease.

Szelenyi I, Marx D.

Arzneimittelforschung. 2001;51(12):1004-14. Review.

PMID:
11799838
29.

Animal models of bronchial asthma.

Szelenyi I.

Inflamm Res. 2000 Dec;49(12):639-54. Review.

PMID:
11211914
30.

Animal models of allergic rhinitis.

Szelenyi I, Marx D, Jahn W.

Arzneimittelforschung. 2000 Nov;50(11):1037-42. Review.

PMID:
11148861
31.

Indazole-3-oles and indazole-2-ones with anti-inflammatory activity.

Schindler R, Hoefgen N, Heinecke K, Poppe H, Szelenyi I.

Pharmazie. 2000 Nov;55(11):857. No abstract available.

PMID:
11126006
32.

New N-(pyridin-4-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents.

Menciu C, Duflos M, Fouchard F, Le Baut G, Emig P, Achterrath U, Szelenyi I, Nickel B, Schmidt J, Kutscher B, Günther E.

J Med Chem. 1999 Feb 25;42(4):638-48.

PMID:
10052971
33.

Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs.

Dent G, Poppe H, Egerland J, Marx D, Szelenyi I, Branscheid D, Magnussen H, Rabe KF.

Pulm Pharmacol Ther. 1998 Feb;11(1):13-21.

PMID:
9802959
34.

1,5-Disubstituted indazol-3-ols with anti-inflammatory activity.

Schindler R, Fleischhauer I, Höfgen N, Sauer W, Egerland U, Poppe H, Heer S, Szelenyi I, Kutscher B, Engel J.

Arch Pharm (Weinheim). 1998 Jan;331(1):13-21.

PMID:
9507697
35.

Experimental studies on acute and chronic action of azelastine on nasal mucosa in guinea pigs, rats and dogs.

Achterrath-Tuckermann U, Berthold K, Roux J, Procter BG, McDonald P, Szelenyi I, Sofia RD, Herbst M.

Arzneimittelforschung. 1997 Nov;47(11):1230-2.

PMID:
9428980
36.

Quantification of rigidity and tremor activity in rats by using a new device and its validation by different classes of drugs.

Nickel B, Kolasiewicz W, Szelenyi I.

Arzneimittelforschung. 1997 Oct;47(10):1081-6.

PMID:
9368698
37.

Antinociceptive effects of R(-)- and S(+)-flurbiprofen on rat spinal dorsal horn neurons rendered hyperexcitable by an acute knee joint inflammation.

Neugebauer V, Geisslinger G, Rümenapp P, Weiretter F, Szelenyi I, Brune K, Schaible HG.

J Pharmacol Exp Ther. 1995 Nov;275(2):618-28.

PMID:
7473147
38.

Effect of phosphodiesterase inhibition on IL-4 and IL-5 production of the murine TH2-type T cell clone D10.G4.1.

Schmidt J, Hatzelmann A, Fleissner S, Heimann-Weitschat I, Lindstaedt R, Szelenyi I.

Immunopharmacology. 1995 Sep;30(3):191-8.

PMID:
8557518
39.

Synergistic protective effects with azelastine and salbutamol in a guinea pig asthma model.

Chand N, Achterrath-Tuckermann U, Szelenyi I, Sofia RD.

Res Commun Mol Pathol Pharmacol. 1995 Feb;87(2):125-32.

PMID:
7749650
40.

5-HT3 receptor antagonism by anpirtoline, a mixed 5-HT1 receptor agonist/5-HT3 receptor antagonist.

Göthert M, Hamon M, Barann M, Bönisch H, Gozlan H, Laguzzi R, Metzenauer P, Nickel B, Szelenyi I.

Br J Pharmacol. 1995 Jan;114(2):269-74.

41.

Evaluation of physical dependence liability of l-deprenyl (selegiline) in animals.

Nickel B, Szelenyi I, Schulze G.

Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):757-67.

PMID:
7995018
42.

Histamine increases anti-CD3 induced IL-5 production of TH2-type T cells via histamine H2-receptors.

Schmidt J, Fleissner S, Heimann-Weitschat I, Lindstaedt R, Szelenyi I.

Agents Actions. 1994 Oct;42(3-4):81-5.

PMID:
7879707
43.
44.

The effect of different corticosteroids and cyclosporin A on interleukin-4 and interleukin-5 release from murine TH2-type T cells.

Schmidt J, Fleissner S, Heimann-Weitschat I, Lindstaedt R, Szelenyi I.

Eur J Pharmacol. 1994 Aug 1;260(2-3):247-50.

PMID:
7988651
45.

Effect of corticosteroids, cyclosporin A, and methotrexate on cytokine release from monocytes and T-cell subsets.

Schmidt J, Fleissner S, Heimann-Weitschat I, Lindstaedt R, Pomberg B, Werner U, Szelenyi I.

Immunopharmacology. 1994 May-Jun;27(3):173-9.

PMID:
8071057
46.
47.

[New central analgesic-acting triaminopyridines].

Emig P, Nickel B, Weischer CH, Szelenyi I, Engel J.

Arzneimittelforschung. 1993 Jun;43(6):627-31. German.

PMID:
8352814
48.

Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats.

Yasar S, Schindler CW, Thorndike EB, Szelenyi I, Goldberg SR.

J Pharmacol Exp Ther. 1993 Apr;265(1):1-6.

PMID:
8473997
49.
50.

Influence of flupirtine, a novel nonopioid analgesic agent on somatosensory evoked potentials in rats.

Nagymajtenyi L, Nickel B, Desi I, Szelenyi I.

Experientia. 1992 Oct 15;48(10):992-3.

PMID:
1426152

Supplemental Content

Loading ...
Support Center